Tejara Capital Ltd Increases Stake in Cardiol Therapeutics Inc.

Tejara Capital Ltd has filed a Schedule 13G with the SEC, disclosing an increased ownership of 5.2% in Cardiol Therapeutics Inc. The filing indicates that Tejara Capital Ltd, a fund manager authorized by the FCA in the UK, now holds 5,130,122 Class A Common Shares plus 1,250,000 warrants. This represents a significant increase in both the number of shares and the value of the holdings, with the value of the shares rising by 37.45% and the number of shares increasing by 57.09%. The filing also notes that the additional shares acquired, which led to the holding exceeding 5%, are still to be registered for trading in the US and cannot be traded until this process is completed. The filing was signed by Miyan Mansur Mannan, Director of Tejara Capital Ltd, on October 23, 2025.